Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BA-3182 by BioAtla for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
BA-3182 is under clinical development by BioAtla and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
BA-3182 by BioAtla for Adenocarcinoma: Likelihood of Approval
BA-3182 is under clinical development by BioAtla and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase II drugs...
BA-3182 by BioAtla for Non-Small Cell Lung Cancer: Likelihood of Approval
BA-3182 is under clinical development by BioAtla and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
BA-3182 by BioAtla for Small-Cell Lung Cancer: Likelihood of Approval
BA-3182 is under clinical development by BioAtla and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...
BA-3182 by BioAtla for Pancreatic Cancer: Likelihood of Approval
BA-3182 is under clinical development by BioAtla and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
BA-3182 by BioAtla for Colon Cancer: Likelihood of Approval
BA-3182 is under clinical development by BioAtla and currently in Phase II for Colon Cancer. According to GlobalData, Phase II...
BA-3182 by BioAtla for Colorectal Cancer: Likelihood of Approval
BA-3182 is under clinical development by BioAtla and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
BA-3182 by BioAtla for Prostate Cancer: Likelihood of Approval
BA-3182 is under clinical development by BioAtla and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II...